Unveiling wild-type transthyretin cardiac amyloidosis as a significant and potentially modifiable cause of heart failure with preserved ejection fraction

Tafamidis in Transthyretin Amyloid Cardiomyopathy: Effects on Transthyretin Stabilization and Clinical Outcomes

(2015) M. S. Maurer et al.   Circulation-Heart Failure

Bone scintigraphy with99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis

(2014) Andor W. J. M. Glaudemans et al.   AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

(2014) Candida Cristina Quarta et al.   CIRCULATION

HFpEF

(2014) Mathew S. Maurer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

99m Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses

(2013) Sabahat Bokhari et al.   Circulation-Cardiovascular Imaging

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis

(2013) Teresa Coelho et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction

(2012) Selma F. Mohammed et al.   Circulation-Heart Failure

Guidelines on the management of valvular heart disease (version 2012)

(2012) et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin

(2010) Taslima Bhuiyan et al.   Circulation-Heart Failure

Systemic Cardiac Amyloidoses

(2009) Claudio Rapezzi et al.   CIRCULATION